Faster, cheaper, safer, T-cell engineering

doi:10.1097/CJI.0b013e3182791257

Comment

. 2013 Jan;36(1):1-2.

doi: 10.1097/CJI.0b013e3182791257.

Faster, cheaper, safer, T-cell engineering

Richard A Morgan¹

Affiliations

PMID: 23211627
PMCID: PMC3521862
DOI: 10.1097/CJI.0b013e3182791257

Comment

Faster, cheaper, safer, T-cell engineering

Richard A Morgan. J Immunother. 2013 Jan.

. 2013 Jan;36(1):1-2.

doi: 10.1097/CJI.0b013e3182791257.

Author

Richard A Morgan¹

Affiliation

¹ Surgery Branch, National Cancer Institute, Bethesda, MD. 20892, USA. rmorgan@mail.nih.gov

PMID: 23211627
PMCID: PMC3521862
DOI: 10.1097/CJI.0b013e3182791257

No abstract available

PubMed Disclaimer

Comment on

Evaluation of long-term transgene expression in piggyBac-modified human T lymphocytes.
Nakazawa Y, Saha S, Galvan DL, Huye L, Rollins L, Rooney CM, Wilson MH. Nakazawa Y, et al. J Immunother. 2013 Jan;36(1):3-10. doi: 10.1097/CJI.0b013e3182791234. J Immunother. 2013. PMID: 23211626 Free PMC article.

Cited by

Trial Watch: Adoptive cell transfer for anticancer immunotherapy.
Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Vacchelli E, et al. Oncoimmunology. 2013 May 1;2(5):e24238. doi: 10.4161/onci.24238. Oncoimmunology. 2013. PMID: 23762803 Free PMC article.
piggyBac-transposon-mediated CAR-T cells for the treatment of hematological and solid malignancies.
Yagyu S, Nakazawa Y. Yagyu S, et al. Int J Clin Oncol. 2023 Jun;28(6):736-747. doi: 10.1007/s10147-023-02319-9. Epub 2023 Mar 2. Int J Clin Oncol. 2023. PMID: 36859566 Review.
Autologous antigen-presenting cells efficiently expand piggyBac transposon CAR-T cells with predominant memory phenotype.
Nakamura K, Yagyu S, Hirota S, Tomida A, Kondo M, Shigeura T, Hasegawa A, Tanaka M, Nakazawa Y. Nakamura K, et al. Mol Ther Methods Clin Dev. 2021 Mar 23;21:315-324. doi: 10.1016/j.omtm.2021.03.011. eCollection 2021 Jun 11. Mol Ther Methods Clin Dev. 2021. PMID: 33898630 Free PMC article.
PiggyBac Transposon-Mediated CD19 Chimeric Antigen Receptor-T Cells Derived From CD45RA-Positive Peripheral Blood Mononuclear Cells Possess Potent and Sustained Antileukemic Function.
Suematsu M, Yagyu S, Nagao N, Kubota S, Shimizu Y, Tanaka M, Nakazawa Y, Imamura T. Suematsu M, et al. Front Immunol. 2022 Jan 27;13:770132. doi: 10.3389/fimmu.2022.770132. eCollection 2022. Front Immunol. 2022. PMID: 35154098 Free PMC article.

References

1. Hackett PB, Largaespada DA, Cooper LJ. A transposon and transposase system for human application. Mol Ther. 2010;18:674–683. - PMC - PubMed
1. Ivics Z, Izsvak Z. Transposons for gene therapy! Curr Gene Ther. 2006;6:593–607. - PubMed
1. Manuri PV, Wilson MH, Maiti SN, et al. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther. 2010;21:427–437. - PMC - PubMed
1. Peng PD, Cohen CJ, Yang S, et al. Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Ther. 2009 - PMC - PubMed
1. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119:2709–2720. - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations

[1] Hackett PB, Largaespada DA, Cooper LJ. A transposon and transposase system for human application. Mol Ther. 2010;18:674–683. - PMC - PubMed

[2] Hackett PB, Largaespada DA, Cooper LJ. A transposon and transposase system for human application. Mol Ther. 2010;18:674–683. - PMC - PubMed

[3] Ivics Z, Izsvak Z. Transposons for gene therapy! Curr Gene Ther. 2006;6:593–607. - PubMed

[4] Ivics Z, Izsvak Z. Transposons for gene therapy! Curr Gene Ther. 2006;6:593–607. - PubMed

[5] Manuri PV, Wilson MH, Maiti SN, et al. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther. 2010;21:427–437. - PMC - PubMed

[6] Manuri PV, Wilson MH, Maiti SN, et al. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther. 2010;21:427–437. - PMC - PubMed

[7] Peng PD, Cohen CJ, Yang S, et al. Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Ther. 2009 - PMC - PubMed

[8] Peng PD, Cohen CJ, Yang S, et al. Efficient nonviral Sleeping Beauty transposon-based TCR gene transfer to peripheral blood lymphocytes confers antigen-specific antitumor reactivity. Gene Ther. 2009 - PMC - PubMed

[9] Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119:2709–2720. - PMC - PubMed

[10] Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119:2709–2720. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Faster, cheaper, safer, T-cell engineering

Affiliation

Faster, cheaper, safer, T-cell engineering

Author

Affiliation

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources